LAUSR

Juan P. Alderuccio, Weiyun Z. Ai, John Radford, Melhem Solh, Kirit M. Ardeshna, Matthew A. Lunning, Brian T. Hess, Pier L. Zinzani, Anastasios Stathis, Carmelo Carlo-Stella, Mehdi Hamadani, Brad S. Kahl, David Ungar, Turk Kilavuz, Eric Yu, Yajuan Qin, and Paolo F. Caimi Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, FL; Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA; The Christie National Health Service (NHS) Foundation Trust, Manchester Cancer Research Centre and Manchester Academic Health Science Centre, Manchester, United Kingdom; Blood and Marrow Transplant Program, Northside Hospital Cancer Institute, Atlanta, GA; Department of Haematology, University College of London Hospitals NHS Foundation Trust, London, United Kingdom; Division of Hematology and Oncology, University of Nebraska Medical Center, Omaha, NE; Hollings Medical Cancer Center, Medical University of South Carolina, Charleston, SC; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Ser agnoli” and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Universit a di Bologna, Bologna, Italy; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Humanitas University and Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Humanitas Research Hospital, Milano, Italy; Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI; Division of Oncology, Washington University, St Louis, MO; Clinical Development, ADC Therapeutics America, Murray Hill, NJ; and Division of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH